Sponsor study identifier
interventional
100
0 countries
N/A
Study Start
January 5, 2017
Actual (reported)Primary Completion
September 8, 2017
Actual (reported)Study Completion
September 8, 2017
Actual (reported)The objective of the investigators was to delineate the efficacy and safety of Ombitasvir, paritaprevir with ritonavir (OBV/PTV/r) plus ribavirin (RBV) on chronic HCV GT4 Egyptian naïve patients
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 8, 2017
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 5, 2017
Actual (reported)September 8, 2017
Actual (reported)September 8, 2017
Actual (reported)May 1, 2020
Actual (reported)May 7, 2020
Actual (reported)Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
SVR12 was defined as hepatitis C virus ribonucleic acid (HCV RNA) level less than 12 IU/mL 12 weeks after the last dose of study drug.
12 weeks after last dose
adverse event (AE)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation observed after administering a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is an event that results in, death, participant hospitalization, life-threatening, significant disability/incapacity, or a congenital anomaly.
Screening up to 30 days after last dose
Percentage of Participants With Post-treatment Relapse Within 12 Weeks Following End of Treatment
Up to 12 weeks after last dose
Administering Ombitasvir/Paritaprevir/Ritonavir/ tablets plus RBV tablets to HCV GT4 in the treatment of Egyptian naïve patients
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Abdel-Moneim A, Aboud A, Abdel-Gabbar M, Zanaty M, Ramadan M. Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients. Dig Dis Sci. 2018 May;63(5):1341-1347. doi: 10.1007/s10620-018-5005-8. Epub 2018 Mar 15.
Mohammed Abdel-Gabbar, Ass. Prof
Biochemistry Dep., Faculty of Science, Beni-Suef University, P.O. Box 52621
100 participants (actual enrollment reported by the registry).
First Submitted
May 1, 2020
First Posted
May 7, 2020
Study Start
January 5, 2017
Contact the study team to confirm eligibility.
Primary Completion
September 8, 2017
Actual (reported)Study Completion
September 8, 2017
Actual (reported)Last Updated
May 12, 2020
Record last verified: 2020-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: